Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Habermann

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
JAMA|October 17, 2002
Medical residents' emotional well-beingTait Shanafelt, Thomas Habermann
The Oncologist|March 12, 2026
Limited Discriminatory Performance of the iMCD-IPI in a Western CohortYoshito Nishimura, Thomas Habermann, Angela Dispenzieri
American Journal of Hematology|October 27, 2025
Comparative Safety of Tocilizumab and Siltuximab in Castleman Disease: Pharmacovigilance StudyYoshito Nishimura, Thomas Habermann, Angela Dispenzieri
Leukemia & Lymphoma|December 11, 2007
Lenalidomide-associated hypothyroidismSmitha Menon, Thomas Habermann, Thomas Witzig
Expert Opinion on Biological Therapy|July 9, 2026
Treating Castleman disease: insights into the use and efficacy of monoclonal antibodiesYoshito Nishimura, Thomas Habermann, Angela Dispenzieri, et al.
American Journal of Hematology|May 8, 2026
Real-World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman DiseaseYoshito Nishimura, Maria Santiago Estevez, Hakeem Asad, et al.
Renal Failure|August 3, 2005
Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodiumLourdes Peña de la Vega, Fernando C Fervenza, Donna Lager, et al.
Journal of Cancer Survivorship : Research and Practice|April 28, 2019
Impact of lymphoma survivorship clinic visit on patient-centered outcomesPaul Viscuse, Kathleen J Yost, Sarah Jenkins, et al.
Journal of General Internal Medicine|July 30, 2005
Relationship between increased personal well-being and enhanced empathy among internal medicine residentsTait D Shanafelt, Colin West, Xinghua Zhao, et al.
American Journal of Hematology|September 16, 2010
Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratioLuis F Porrata, Kay Ristow, Thomas Habermann, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
JAMA|October 17, 2002
Medical residents' emotional well-beingTait Shanafelt, Thomas Habermann
The Oncologist|March 12, 2026
Limited Discriminatory Performance of the iMCD-IPI in a Western CohortYoshito Nishimura, Thomas Habermann, Angela Dispenzieri
American Journal of Hematology|October 27, 2025
Comparative Safety of Tocilizumab and Siltuximab in Castleman Disease: Pharmacovigilance StudyYoshito Nishimura, Thomas Habermann, Angela Dispenzieri
Leukemia & Lymphoma|December 11, 2007
Lenalidomide-associated hypothyroidismSmitha Menon, Thomas Habermann, Thomas Witzig
Expert Opinion on Biological Therapy|July 9, 2026
Treating Castleman disease: insights into the use and efficacy of monoclonal antibodiesYoshito Nishimura, Thomas Habermann, Angela Dispenzieri, et al.
American Journal of Hematology|May 8, 2026
Real-World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman DiseaseYoshito Nishimura, Maria Santiago Estevez, Hakeem Asad, et al.
Renal Failure|August 3, 2005
Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodiumLourdes Peña de la Vega, Fernando C Fervenza, Donna Lager, et al.
Journal of Cancer Survivorship : Research and Practice|April 28, 2019
Impact of lymphoma survivorship clinic visit on patient-centered outcomesPaul Viscuse, Kathleen J Yost, Sarah Jenkins, et al.
Journal of General Internal Medicine|July 30, 2005
Relationship between increased personal well-being and enhanced empathy among internal medicine residentsTait D Shanafelt, Colin West, Xinghua Zhao, et al.
American Journal of Hematology|September 16, 2010
Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratioLuis F Porrata, Kay Ristow, Thomas Habermann, et al.
Pageof 4